These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 32311641

  • 1. Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders.
    Sahin T, Yilmaz R, Akbostanci MC.
    Parkinsonism Relat Disord; 2020 May; 74():36-37. PubMed ID: 32311641
    [No Abstract] [Full Text] [Related]

  • 2. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ, Ondo WG, Dashtipour K, Swope DM.
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [Abstract] [Full Text] [Related]

  • 3. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
    Jankovic J, Orman J.
    Neurology; 1988 Mar; 38(3):391-4. PubMed ID: 3279337
    [Abstract] [Full Text] [Related]

  • 4. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR.
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
    [Abstract] [Full Text] [Related]

  • 5. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C, Jankovic J.
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [Abstract] [Full Text] [Related]

  • 6. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
    Koch J, Shi WX, Dashtipour K.
    Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050
    [Abstract] [Full Text] [Related]

  • 7. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM.
    Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
    [Abstract] [Full Text] [Related]

  • 8. [Therapeutic use of tetrabenazine].
    López Del Val LJ, López-García E, Martínez-Martínez L, Santos-Lasaosa S.
    Rev Neurol; 2017 Feb; 48(10):523-33. PubMed ID: 19434587
    [Abstract] [Full Text] [Related]

  • 9. Valbenazine-induced parkinsonism.
    Akbar U, Kim DS, Friedman JH.
    Parkinsonism Relat Disord; 2020 Jan; 70():13-14. PubMed ID: 31785443
    [No Abstract] [Full Text] [Related]

  • 10. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr 23; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract] [Full Text] [Related]

  • 11. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
    Jankovic J, Clarence-Smith K.
    Expert Rev Neurother; 2011 Nov 23; 11(11):1509-23. PubMed ID: 22014129
    [Abstract] [Full Text] [Related]

  • 12. Tetrabenazine treatment in movement disorders.
    Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S.
    Clin Neuropharmacol; 2004 Nov 23; 27(5):230-3. PubMed ID: 15602104
    [Abstract] [Full Text] [Related]

  • 13. Tetrabenazine for the treatment of tardive dyskinesia.
    Leung JG, Breden EL.
    Ann Pharmacother; 2011 Apr 23; 45(4):525-31. PubMed ID: 21487088
    [Abstract] [Full Text] [Related]

  • 14. Alpha methylparatyrosine and tetrabenazine in movement disorders.
    Lang AE, Marsden CD.
    Clin Neuropharmacol; 1982 Dec 23; 5(4):375-87. PubMed ID: 6130839
    [Abstract] [Full Text] [Related]

  • 15. Tetrabenazine.
    Fasano A, Bentivoglio AR.
    Expert Opin Pharmacother; 2009 Dec 23; 10(17):2883-96. PubMed ID: 19929707
    [Abstract] [Full Text] [Related]

  • 16. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J.
    Expert Opin Pharmacother; 2016 Dec 23; 17(18):2461-2470. PubMed ID: 27819145
    [Abstract] [Full Text] [Related]

  • 17. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA, Proctor GJ, Stahl SM.
    Clin Schizophr Relat Psychoses; 2018 Jan 23; 11(4):214-220. PubMed ID: 29341821
    [Abstract] [Full Text] [Related]

  • 18. Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington's disease.
    Moondra P, Jimenez-Shahed J.
    Expert Rev Neurother; 2024 Sep 23; 24(9):849-863. PubMed ID: 38982802
    [Abstract] [Full Text] [Related]

  • 19. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Jankovic J.
    Adv Neurol; 1983 Sep 23; 37():277-89. PubMed ID: 6574695
    [No Abstract] [Full Text] [Related]

  • 20. Deuterated Drug Molecules: Focus on FDA-Approved DeutetrabenazinePublished as part of the Biochemistry series "Biochemistry to Bedside".
    DeWitt SH, Maryanoff BE.
    Biochemistry; 2018 Feb 06; 57(5):472-473. PubMed ID: 29160059
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.